Every year, opioid overdose deaths claim tens of thousands of lives across the United States, and Maryland consistently ranks among the states hardest hit by the crisis. Extended-release buprenorphine weekly injection is one of the most significant advances in opioid use disorder treatment in recent years, offering a clinically proven alternative to daily medication that removes one of the most common barriers to staying in treatment: remembering to take a dose every single day.
What Extended-Release Buprenorphine Weekly Is
Weekly extended-release buprenorphine is a subcutaneous injection administered once per week that delivers a steady, controlled dose of buprenorphine over seven days. The branded formulation available in the United States is Brixadi, which comes in both weekly and monthly dosing options. The weekly version is the focus here. Rather than taking a film or tablet under your tongue each morning, you receive a single injection at a clinic visit, and the medication works continuously from there.
The stakes for getting treatment right are real. According to the CDC, more than 80,000 Americans died from opioid overdoses in 2023, with synthetic opioids like fentanyl driving the overwhelming majority of those deaths. In Maryland, the Maryland Department of Health reported over 2,900 overdose fatalities in 2022 alone, making access to effective, flexible treatment options a matter of life and death for people across the state.
How It Differs from Daily Sublingual Buprenorphine
Daily sublingual buprenorphine, taken as a film or tablet that dissolves under the tongue, produces peaks and troughs in plasma concentration throughout the day. Your blood levels of buprenorphine rise after you take your dose and fall as the hours pass. For many people, those fluctuations are subtle. For others, they translate into mild cravings as the dose wears off, or a morning rush of sedation right after dosing.
A 2022 pharmacokinetic analysis published in the journal Clinical Pharmacokinetics compared plasma concentration profiles across buprenorphine formulations and found that subcutaneous extended-release formulations produced significantly more stable steady-state plasma levels compared to sublingual administration. What stable levels mean in daily life is straightforward: fewer cravings tied to dose timing, no daily decision about whether you’ve taken your medication, and no risk of missing a dose because the week got complicated. The medication is simply working, continuously, in the background.
The Active Ingredient and How It Works in the Body
Buprenorphine is a partial agonist at the mu-opioid receptor, which is the receptor that opioids like heroin, fentanyl, and prescription painkillers bind to when they produce their effects. A full agonist activates that receptor completely. Buprenorphine activates it partially, which is what makes it useful for treatment.
At the mu-opioid receptor, buprenorphine binds with very high affinity, meaning it holds on tightly and displaces other opioids. It activates the receptor enough to eliminate withdrawal symptoms and reduce cravings, but it has what pharmacologists call a ceiling effect: beyond a certain dose, increasing the amount of buprenorphine in your system does not produce proportionally greater respiratory depression. A 2006 study published in Addiction Biology examining buprenorphine’s receptor binding characteristics confirmed that this ceiling effect on respiratory depression is a key pharmacological property that distinguishes buprenorphine from full agonist opioids and is central to its safety profile in opioid use disorder treatment.
Who Qualifies for Weekly ER Buprenorphine
The typical candidate for weekly ER buprenorphine is an adult with opioid use disorder who is either already stabilized on buprenorphine or who is experiencing mild-to-minimal opioid withdrawal at the time of the first injection. A 2022 study published in JAMA Network Open examining clinical criteria for extended-release buprenorphine initiation found that patients in mild or minimal withdrawal, defined by a Clinical Opiate Withdrawal Scale score of 8 or below, achieved successful induction without precipitated withdrawal at rates comparable to patients with more significant withdrawal scores.
For Maryland patients covered by Medicaid, access to Brixadi has improved meaningfully in recent years. Maryland Medicaid covers FDA-approved buprenorphine formulations for opioid use disorder, and the weekly injectable formulation has been added to the Maryland Medicaid formulary without the prior authorization barriers that once made newer formulations harder to access. If you’re on Medicaid in Maryland, this option is likely available to you.
Starting Directly on the Weekly Injection
A common question is whether someone who has never taken buprenorphine before needs to start with sublingual tablets or films before transitioning to the injection. The answer is no, not necessarily. The JAMA Network Open study referenced above specifically examined minimal-withdrawal initiation with extended-release injectable buprenorphine in opioid-naive patients, meaning those who had not recently been on buprenorphine, and found that direct initiation was clinically feasible when withdrawal was at mild-to-minimal levels.
On day one of your first injection, the medication begins reaching therapeutic plasma levels within hours. Most patients report that withdrawal symptoms ease noticeably within the first day, with cravings reducing significantly by the second and third day as levels stabilize. Your provider will monitor you at the clinic after the injection before clearing you to leave.
Patients Who May Not Be the Right Fit
Not everyone is a candidate for weekly injectable buprenorphine, and your provider will screen for this before your first dose. Severe hepatic impairment is a contraindication, because buprenorphine is metabolized by the liver and impaired liver function can significantly alter how the medication behaves. Known hypersensitivity to buprenorphine or to any component of the injection formulation also rules out this option. Certain co-occurring medical conditions may require additional evaluation before proceeding.
For people who are pregnant, the picture requires more nuance. A 2023 analysis published in Contemporary OB/GYN examining weekly extended-release buprenorphine in pregnancy found maternal and neonatal safety profiles comparable to sublingual formulations, though the authors emphasized that the decision requires close coordination between the OUD treatment provider and the obstetric team. If you are pregnant or planning to become pregnant, raise this explicitly with both providers at the earliest opportunity.
What the Injection Process Actually Looks Like
The injection itself is straightforward. Brixadi is administered subcutaneously, meaning just beneath the skin, typically in the abdomen or upper arm. A certified provider places the injection during a scheduled clinic visit. The appointment is not lengthy; most patients spend 30 to 60 minutes at the clinic, which includes check-in, a brief clinical assessment, the injection, and a short observation period.
A 2021 patient satisfaction study published in Drug and Alcohol Dependence surveyed 200 patients receiving injectable versus sublingual buprenorphine and found that patients on the injectable formulation reported significantly higher satisfaction with their treatment experience, citing reduced daily treatment burden and greater sense of stability as primary drivers. For patients who have spent months or years managing daily sublingual medication, the transition often feels like a meaningful reduction in the mental load that treatment carries.
The Injection Site and What to Expect Physically
After the injection, you will likely notice a small lump or nodule at the injection site. This is the depot, the subcutaneous reservoir of medication that releases buprenorphine gradually over the week. It is normal, expected, and is the mechanism by which the extended-release effect works. The depot typically reduces in size as the medication is absorbed, and most patients find it has resolved substantially by the end of the week.
Mild redness, tenderness, or itching at the injection site is common in the first 24 to 48 hours. These reactions are typically minor and resolve on their own without intervention. Over time, rotating injection sites across the abdomen or upper arms helps minimize localized tissue changes and keeps any one area from becoming consistently irritated.
Your Dosing Schedule and What Happens If You Miss a Visit
The cadence is once weekly, and keeping that schedule is the simplest version of managing your treatment. If your appointment falls on a holiday or a scheduling conflict comes up, contact the clinic in advance. A delay of one to two days is generally manageable clinically, and your provider can advise on the appropriate course of action. A longer gap requires a clinical conversation before your next injection, because extended gaps can affect plasma levels and withdrawal status.
The NHS guidance on missed buprenorphine doses, while developed for the UK context, reflects the same underlying pharmacology: a brief delay is not a treatment failure, but communication with your care team is the right move when any disruption to your schedule is anticipated. Don’t wait until your scheduled appointment has passed. Call the clinic when you know the conflict is coming.
How Dosing Is Determined and Adjusted
Weekly ER buprenorphine is not a one-size-fits-all medication, and your starting dose is calculated based on your individual situation. If you are transitioning from sublingual buprenorphine, your provider will use your current daily sublingual dose to determine the equivalent weekly injectable dose. If you are initiating directly, your provider will assess your current withdrawal severity and opioid use history to select a starting point. Brixadi is available in multiple weekly dose strengths, including 8 mg, 16 mg, and 24 mg, which gives providers the flexibility to match the dose to where you are in treatment rather than forcing a single standard approach.
A 2020 pharmacology review in the British Journal of Clinical Pharmacology examining buprenorphine dose-response relationships found that therapeutic effect plateaus at higher doses due to the ceiling effect at the mu-opioid receptor, but that meaningful clinical differences exist across the lower dose range, making individualized dose selection important for optimizing outcomes.
Moving From Sublingual to the Weekly Injection
If you are currently taking sublingual buprenorphine and want to switch to the weekly injection, the transition process is well-defined. Your provider will confirm that you are clinically stable on your current sublingual dose, meaning cravings are controlled, you are not experiencing withdrawal between doses, and your medication is working. From there, the last sublingual dose is timed appropriately before the first injection, and your provider determines the equivalent weekly injectable dose based on published conversion data.
“Stabilized” in this context means your sublingual dose has been consistent for a period of time and is effectively managing your OUD symptoms. Your provider makes this determination based on your reported experience and, in many cases, urine drug screening results. If you have been on sublingual buprenorphine for a while and are interested in switching, the conversation with your provider is the first step, and most transitions can be planned within a few weeks. You can learn more about what the full Brixadi treatment process involves to understand what to expect at each stage.
Adjusting Your Dose Over Time
Once you are on the weekly injection, your dose is not locked in permanently. If you are experiencing persistent cravings between injections, that is a signal that your dose may need to go up. If you are having side effects that feel disproportionate, that is a signal to discuss whether a lower dose is appropriate. Because the injection is administered weekly, dose adjustments happen at your next weekly visit, which means changes can be implemented relatively quickly compared to monthly injectable formulations.
A 2022 titration outcomes study published in the Journal of Addiction Medicine found that patients who had dose adjustments made in the first four weeks of extended-release buprenorphine treatment had significantly higher retention rates at 12 weeks compared to patients whose doses were not adjusted despite reported symptoms. The takeaway: if your current dose is not working, say so at your next visit. Tell your provider specifically whether your issue is cravings, withdrawal symptoms between injections, or side effects. That information moves a dose review forward faster than a general complaint.
How Weekly ER Buprenorphine Compares to Other MAT Options
Medication-assisted treatment for opioid use disorder includes several options, and weekly injectable buprenorphine sits within a landscape that also includes daily sublingual buprenorphine/naloxone (Suboxone), monthly injectable buprenorphine (Sublocade), methadone, and naltrexone (Vivitrol). A 2023 systematic review published in The Lancet Psychiatry examined head-to-head retention and efficacy data across MAT options and found that extended-release buprenorphine formulations consistently outperformed daily oral formulations on treatment retention, with injectable formats showing the strongest adherence advantage.
Each option fits a different patient profile and a different stage of recovery. Methadone requires daily clinic attendance and carries more regulatory restrictions. Naltrexone requires complete opioid detoxification before initiation, which is a significant barrier for many people. Daily sublingual buprenorphine works well but demands daily consistency. The injectable formulations remove the daily management burden while maintaining buprenorphine’s established efficacy.
Weekly vs. Monthly Injectable Buprenorphine
Both Brixadi (weekly) and Sublocade (monthly) are subcutaneous extended-release buprenorphine injections, but they serve somewhat different purposes in clinical practice. The most meaningful practical difference is dose flexibility. With a weekly format, if your dose needs to change, the adjustment happens at your next visit, seven days away. With a monthly format, if something is not working, you wait up to a month for the next opportunity to change course.
For patients in early treatment, where dose finding is still underway and providers are learning how your body responds to the medication, the weekly format allows faster course correction. For patients who are well-stabilized and whose dose has been consistent for a long period, the monthly format may offer the appeal of fewer clinic visits. If you are weighing these options, understanding how the weekly buprenorphine injection works in more detail can help you have a more informed conversation with your provider.
Why the Weekly Format Can Support Long-Term Recovery
Weekly clinic visits do more than deliver a medication. They create a consistent point of contact with the care team, which research links directly to better long-term outcomes. A 2020 retention study published in Addiction examined 1,200 patients across buprenorphine treatment formats and found that patients with more frequent scheduled clinic contact in the first 90 days of treatment had a 34% higher rate of retention at one year compared to patients with monthly-only contact.
What those weekly check-ins enable goes beyond the injection itself. A brief clinical conversation at each visit allows your provider to track how you are feeling, identify emerging mental health concerns, review drug screening results, and adjust the overall care plan. For patients managing co-occurring conditions like depression or anxiety, that consistent touchpoint is not a minor administrative detail. It is an active component of treatment.
Effectiveness: What the Research Shows
The clinical trial data on weekly extended-release buprenorphine is strong. The pivotal Phase 3 trial published in JAMA Network Open followed 428 adults with opioid use disorder randomized to weekly or monthly injectable buprenorphine versus daily sublingual buprenorphine/naloxone. At 24 weeks, patients on the injectable formulations had significantly higher rates of opioid-negative urine screens and significantly higher rates of treatment retention compared to the daily sublingual group. Translated into plain language: more people stayed in treatment, and more people were not using opioids while in treatment.
The trial’s retention finding is worth sitting with. Staying in treatment is itself the most powerful predictor of long-term recovery outcomes. A medication that makes it easier to stay in treatment is doing something clinically significant, independent of any other benefit.
Effectiveness for People Using Fentanyl
If fentanyl is what you have been using, you are not alone among Maryland patients, and it is reasonable to ask whether treatment data from older clinical trials applies to you. Historically, clinical trials for buprenorphine formulations underrepresented people with high fentanyl use, because many trials were designed before illicitly manufactured fentanyl dominated the drug supply. A 2023 study published in Drug and Alcohol Dependence specifically examined buprenorphine treatment outcomes in patients with fentanyl-positive urine screens at baseline and found that extended-release buprenorphine formulations performed comparably to what earlier trials showed in heroin-predominant populations, with high rates of opioid-negative screens by weeks four through eight.
What this means for your treatment outcome: fentanyl use history does not make you a poor candidate for weekly ER buprenorphine. The buprenorphine still binds the mu-opioid receptor, still eliminates withdrawal, and still reduces cravings. The initiation process may require more careful monitoring in the first 24 to 48 hours, but that is a clinical management question, not a reason to avoid treatment.
Effectiveness Compared to No Treatment
The most direct way to understand whether weekly ER buprenorphine is worth pursuing is to consider the alternative. A 2021 epidemiological study published in the New England Journal of Medicine tracking 40,000 patients diagnosed with opioid use disorder found that those who received medication-assisted treatment had an overdose mortality rate 2.1 times lower than those who received no medication. That is not a marginal difference. Left untreated, opioid use disorder carries a mortality risk that dwarfs almost any other chronic condition that Americans manage without medical intervention.
The question is not whether any medication is perfect. No treatment for any chronic condition is. The question is whether extended-release buprenorphine meaningfully reduces the risk of death and helps you rebuild a functional life, and the evidence says yes.
Side Effects and Safety
Weekly ER buprenorphine has a well-characterized safety profile, established through both pre-approval clinical trials and post-market surveillance. The FDA’s review of Brixadi’s clinical data, which formed the basis of approval, documented side effects as manageable and largely predictable. The safety profile is not a secret or an afterthought. It is well-studied, and most patients tolerate the medication without serious complications.
Common Side Effects at the Injection Site
Injection-site reactions are the most frequently reported side effects with weekly subcutaneous buprenorphine. These include nodule formation at the depot site, bruising, mild pain, itching, and localized redness. The nodule forms because the medication is deposited in the subcutaneous tissue and releases gradually; this is the intended mechanism, not a problem. Most injection-site reactions resolve within one to two weeks and diminish further as your body becomes accustomed to the depot.
In the 24 hours after your injection, keeping the area clean, avoiding tight clothing over the site, and not massaging or pressing on the nodule helps minimize discomfort and supports normal drug delivery. If redness, warmth, or pain at the injection site worsens significantly after 72 hours rather than improving, contact the clinic. That pattern is uncommon but worth reporting.
Systemic Side Effects to Know About
Beyond the injection site, the most commonly reported systemic side effects with weekly ER buprenorphine include constipation, headache, nausea, insomnia, and sweating. Constipation is the most persistent of these; it is a class effect of opioid medications, including partial agonists, and tends not to resolve on its own without dietary adjustments or over-the-counter management. Nausea and headache are most common in the first one to two weeks of treatment and typically diminish as plasma levels stabilize.
The Phase 3 trial’s adverse event data found that the majority of systemic side effects occurring in the first month of treatment had resolved or significantly improved by week eight. Side effects that persist beyond that window, or that feel severe enough to affect daily function, are worth raising explicitly at your next weekly visit rather than waiting.
Overdose Risk and the Ceiling Effect
Buprenorphine’s ceiling effect on respiratory depression means that at therapeutic doses, the risk of fatal respiratory depression from buprenorphine alone is substantially lower than with full agonist opioids. This is a pharmacological fact that distinguishes buprenorphine from drugs like fentanyl or oxycodone, where dose escalation produces linearly increasing respiratory depression.
The risk scenario that exists is combining buprenorphine with central nervous system depressants, particularly benzodiazepines and alcohol. An FDA safety communication on buprenorphine-benzodiazepine combinations documented that this combination carries a meaningfully elevated risk of adverse respiratory events, even given buprenorphine’s ceiling effect. Before your first injection, tell your provider every medication and substance you are using, including alcohol, benzodiazepines prescribed or otherwise, and any sleep aids. That information shapes your safety profile from day one.
Accessing Weekly ER Buprenorphine in Maryland
Access to buprenorphine treatment has improved significantly since 2023, when the federal requirement for a special X-waiver to prescribe buprenorphine for opioid use disorder was eliminated. Any licensed physician, nurse practitioner, or physician assistant can now prescribe and administer buprenorphine for OUD treatment, which has expanded the number of providers across Maryland substantially. If you are in Baltimore, College Park, Linthicum Heights, Nottingham, Owings Mills, or anywhere else in the state, the provider network is more accessible than it was just a few years ago.
If you are trying to figure out where to get Brixadi in Maryland specifically, the answer starts with identifying a clinic that administers the injectable formulation in office rather than directing you to self-administer at home, which is not how Brixadi works.
What to Expect at Your First Appointment
Your first appointment at an OUD treatment clinic will include an intake assessment covering your substance use history, medical history, current medications, and any co-occurring mental health conditions. A physical examination, basic labs, and urine drug screening are standard. The provider uses all of this information to determine your starting dose and to establish your baseline before any medication is administered.
The most useful thing to bring is a clear, honest account of every medication and substance you have used in the past 30 days. Not because the clinic will judge you for it, but because the information directly shapes your starting dose and your safety profile. If fentanyl is part of your recent use history, say so. If you take benzodiazepines, prescribed or otherwise, say so. The more accurate the picture, the better the starting point. For an overview of what finding a qualified provider in Maryland actually involves, reviewing the criteria beforehand helps you know what questions to ask.
Cost and Insurance Coverage
For Maryland Medicaid patients, Brixadi is covered under the Maryland Medicaid formulary for opioid use disorder treatment. Most commercial insurance plans also cover FDA-approved buprenorphine formulations for OUD, though prior authorization requirements vary by plan. For patients without insurance, the manufacturer of Brixadi (Braeburn) offers a patient assistance program that can significantly reduce or eliminate out-of-pocket costs.
The practical step before your first appointment is to call the clinic’s insurance or billing team and ask them to verify your coverage. Most clinics can complete a benefits check the same day. Knowing your coverage status before you walk in removes one potential source of anxiety from what is already a significant first step.
What to Do This Week
If opioid use disorder is affecting your life or someone you care about, call a Maryland-based buprenorphine provider this week and ask specifically about the weekly injectable option. You do not need to have made any final decisions. This is an information-gathering call, and the question to lead with is simple: “Do you offer the weekly Brixadi injection, and can you walk me through what starting treatment would look like for me?” That one question tells you immediately whether the clinic has what you need and opens the door to a real conversation about fit. The rest follows from there.
